ArticleInternational journal of clinical and experimental pathology2019
Matrilin-2 is a novel prognostic marker in osteosarcoma.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Identification and validation of the potential therapeutic value of CASK in osteosarcoma: a computational analysis andFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOsteosarcoma is the most malignant bone tumor in adolescents. Molecules that are significantly associated with prognosis of osteosarcoma remain to be elucidated. In this study, we aimed to explore the prognostic role of Matrilin-2 (MATN2) in osteosarcoma.
methodsBy in silico analysis, we used GSE42352, GSE33382, and GSE21257 to explore the differential expression in osteosarcoma patients with different tumor status. Tissue and serum levels of MATN2 in 56 osteosarcoma patients were verified by RT-PCR and ELISA kits, respectively. Small interfering RNA was used to interfere with the expression of MATN2 in U-2OS and MG-63. CCK-8 and transwell assay were used to detect cell proliferation and migration, respectively. Western blot was used to detect the expression of invasion-related proteins.
resultsMATN2 was overexpressed both in osteosarcoma cells and tissues when compared to normal controls. Both tissue and serum level of MATN2 correlated with tumor Enneking stage and metastasis status in osteosarcoma patients according to GEO datasets and validation cohort. Further Kaplan-Meier analysis revealed that MATN2 was a novel prognostic marker in patients with osteosarcoma. Knockdown of MATN2 by siRNA significantly reduced the proliferation and invasion of osteosarcoma cells in vivo. Furthermore, inhibition of MATN2 in U-2OS and MG-63 cells dramatically reduced the expression of mmp2, vimentin and snail1.
conclusionElevated MATN2 in tissues and serum significantly associated with both tumor malignancy and poor outcome, which indicates MATN2 could be a prognostic biomarker in patients with osteosarcoma.
Indexed as
Identifiers
31933763PMC6949765W3027090459What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.